Patricia Huelin

Patricia Huelin

Auto-generated profile, based on publicly available information

Patricia Huelin

Liver Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
ESElsa Solà
Elsa Solà
CSCristina Solé
Cristina Solé
MSMacarena Simón-Talero
Macarena Simón-Talero
MMMarta Martín-Llahí
Marta Martín-Llahí
JCJosé Castellote
José Castellote
PGPere Ginès
Pere Ginès

1 March 2017 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PHPatricia Huelin
Patricia Huelin
SPSalvatore Piano
Salvatore Piano
ESElsa Solà
Elsa Solà
MSMarialuisa Stanco
Marialuisa Stanco
CSCristina Solé
Cristina Solé
PGPere Ginès
Pere Ginès

31 August 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CSCristina Solé
Cristina Solé
ESElsa Solà
Elsa Solà
Manuel Morales-RuizManuel Morales-Ruiz
Manuel Morales-Ruiz
GFGuerau Fernàndez
Guerau Fernàndez
PHPatricia Huelin
Patricia Huelin
PGPere Ginès
Pere Ginès
ACLF is characterized by a systemic inflammatory response, but the cytokines involved in this process have not been well studied. The aim of this study was to characterize the systemic inflammatory response in patients with cirrhosis and ACLF and its relationship with prognosis. Fifty-five patients with cirrhosis, 26 with ACLF, were studied prospectively. Systemic inflammatory response was analyzed by measuring a large array of plasma cytokines by using a multiplex kit. A principal component analysis show noticeable differences between ACLF and decompensated cirrhosis without ACLF. Patients with ACLF had significant abnormal levels of 12 cytokines compared to those without ACLF, including: VCAM-1, VEGF-A, Fractalkine, MIP-1α, Eotaxin, IP-10, RANTES, GM-CSF, IL-1β, IL-2, ICAM-1 and MCP-1. Cytokines showing the most marked relationship with ACLF were VCAM-1 and VEGF-A (AUCROC 0.77; p = 0.001). There was a significant relationship between some of inflammatory mediators and 3-month mortality, particularly VCAM-1, ICAM-1 and GM-CSF (AUCROC>0.7; p < 0.05). Functional Enrichment Analysis showed that inflammatory markers differentially expressed in ACLF patients were enriched in leukocyte migration, particularly monocytes and macrophages and chemotaxis pathways. In conclusion, ACLF is characterized by a marked inflammatory reaction with activation of mediators of adhesion and migration of leukocytes. The intensity of the inflammatory reaction correlates with prognosis.

1 July 2016 in Journal of Hepatology
Verified
Journal Article
Open access
XAX. Ariza
X. Ariza
IGI. Graupera
I. Graupera
MCM. Coll
M. Coll
ESE. Solà
E. Solà
RBR. Barreto
R. Barreto
PGP. Ginès
P. Ginès
Acute-on-chronic liver failure (ACLF) is a syndrome that occurs in cirrhosis characterized by organ failure(s) and high mortality rate. There are no biomarkers of ACLF. The LCN2 gene and its product, neutrophil gelatinase-associated lipocalin (NGAL), are upregulated in experimental models of liver injury and cultured hepatocytes as a result of injury by toxins or proinflammatory cytokines, particularly Interleukin-6. The aim of this study was to investigate whether NGAL could be a biomarker of ACLF and whether LCN2 gene may be upregulated in the liver in ACLF. We analyzed urine and plasma NGAL levels in 716 patients hospitalized for complications of cirrhosis, 148 with ACLF. LCN2 expression was assessed in liver biopsies from 29 additional patients with decompensated cirrhosis with and without ACLF. Urine NGAL was markedly increased in ACLF vs. no ACLF patients (108(35-400) vs. 29(12-73)μg/g creatinine; p<0.001) and was an independent predictive factor of ACLF; the independent association persisted after adjustment for kidney function or exclusion of variables present in ACLF definition. Urine NGAL was also an independent predictive factor of 28day transplant-free mortality together with MELD score and leukocyte count (AUROC 0.88(0.83-0.92)). Urine NGAL improved significantly the accuracy of MELD in predicting prognosis. The LCN2 gene was markedly upregulated in the liver of patients with ACLF. Gene expression correlated directly with serum bilirubin and INR (r=0.79; p<0.001 and r=0.67; p<0.001), MELD (r=0.68; p<0.001) and Interleukin-6 (r=0.65; p<0.001). NGAL is a biomarker of ACLF and prognosis and correlates with liver failure and systemic inflammation. There is remarkable overexpression of LCN2 gene in the liver in ACLF syndrome. Urine NGAL is a biomarker of acute-on-chronic liver failure (ACLF). NGAL is a protein that may be expressed in several tissues in response to injury. The protein is filtered by the kidneys due to its small size and can be measured in the urine. Ariza, Graupera and colleagues found in a series of 716 patients with cirrhosis that urine NGAL was markedly increased in patients with ACLF and correlated with prognosis. Moreover, gene coding NGAL was markedly overexpressed in the liver tissue in ACLF.

4 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XAXavier Ariza
Xavier Ariza
ESElsa Solà
Elsa Solà
CEChiara Elia
Chiara Elia
RBRogelio Barreto
Rogelio Barreto
RMRebeca Moreira
Rebeca Moreira
PGPere Ginès
Pere Ginès
Biomarkers are potentially useful in assessment of outcomes in patients with cirrhosis, but information is very limited. Given the large number of biomarkers, adequate choice of which biomarker(s) to investigate first is important. Analysis of potential usefulness of a panel of urinary biomarkers in outcome assessment in cirrhosis. Fifty-five patients with acute decompensation of cirrhosis were studied: 39 had Acute Kidney Injury (AKI) (Prerenal 12, type-1 HRS (hepatorenal syndrome) 15 and Acute Tubular Necrosis (ATN) 12) and 16 acute decompensation without AKI. Thirty-four patients had Acute-on-chronic liver failure (ACLF). A panel of 12 urinary biomarkers was assessed, using a multiplex assay, for their relationship with ATN, ACLF and mortality. Biomarker with best accuracy for ATN diagnosis was NGAL (neutrophil-gelatinase associated lipocalin): 36 [26-125], 104 [58-208] and 1807 [494-3,716] μg/g creatinine in Prerenal-AKI, type-1 HRS and ATN, respectively; p<0.0001 (AUROC 0.957). Other attractive biomarkers for ATN diagnosis were IL-18, albumin, trefoil-factor-3 (TFF-3) and glutathione-S-transferase-π (GST-π) Biomarkers with less accuracy for ATN AUCROC<0.8 were β2-microglobulin, calbindin, cystatin-C, clusterin and KIM-1 (kidney injury molecule-1). For ACLF, the biomarker with the best accuracy was NGAL (ACLF vs. No-ACLF: 165 [67-676] and 32 [19-40] μg/g creatinine; respectively; p<0.0001; AUROC 0.878). Interestingly, other biomarkers with high accuracy for ACLF were osteopontin, albumin, and TFF-3. Biomarkers with best accuracy for prognosis were those associated with ACLF. A number of biomarkers appear promising for differential diagnosis between ATN and other types of AKI. The most interesting biomarkers for ACLF and prognosis are NGAL, osteopontin, albumin, and TFF-3. These results support the role of major inflammatory reaction in the pathogenesis of ACLF.

1 August 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
EAEduardo Albéniz
Eduardo Albéniz
MFMaría Fraile
María Fraile
BIBerta Ibañez-Beroiz
Berta Ibañez-Beroiz
PAPedro Alonso-Aguirre
Pedro Alonso-Aguirre
DMDavid Martínez-Ares
David Martínez-Ares
CGCarlos Guarner-Argente
Carlos Guarner-Argente